Press Releases | Y-mAbs Therapeutics, Inc.

Year

Y-mAbs Announces Presentation of Naxitamab data at AACR

NEW YORK , April 18, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced

Apr 18, 2023

Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA

NEW YORK , April 05, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced

Apr 05, 2023

Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments

Q4 2022 DANYELZA® record net product revenues of $16.4 million , driving YoY growth of 71% and 31% sequential increase compared to Q3 2022 DANYELZA conditional marketing authorization granted in China Management reiterates 2023 financial guidance First ever SADA Phase I trial opened Cash and cash

Mar 30, 2023

Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023

NEW YORK , March 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for year ended December 31, 2022 , on Thursday, March 30, 2023 , after the close of the U.S. financial markets.

Mar 21, 2023

Y-mAbs and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab

NEW YORK , Feb. 02, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced

Feb 02, 2023

Y-mAbs Announces Restructuring Plan and Provides Financial Outlook Following Complete Response Letter from FDA

Estimated 28% reduction in annual operating expenses for 2023 compared to previously announced guidance for 2022 of $162-167 million ; Estimated total cash burn for 2023, including restructuring expenses, expected to be $50-55 million , expected to extend cash runway into Q1 2026 based on revised

Jan 04, 2023

Y-mAbs Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

NEW YORK , Jan. 03, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced

Jan 03, 2023

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 11 - 17 of 17